Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The trial will develop and validate a platform for quantitative assessment of antiviral
effects in low-risk patients with high viral burdens and uncomplicated COVID-19. In this
randomised open label, controlled, group sequential adaptive platform trial, we will assess
the performance of three distinct types of intervention relative to control (no treatment):
A: potentially effective repurposed antiviral drugs;
B: Positive control: we will initially include the REGN-COV2 (monoclonal antibody cocktail);
and later:
C: any future small molecule drugs that pass phase 1 testing.
PLATCOV study is funded by ACT-Accelerator Therapeutics Partnership through the Wellcome
Trust. The grant reference number is 223195/Z/21/Z